22 / 27
Real World Data
• 1L vs 2L: Efficacy and Safety Indicators
Berdelou A, et al. Thyroid. 2017
Patients and methods
•
Retrospective Observational study of all 75 consecutive patients treated with Lenvatinib during the
time of French Compassionate Use Program (ATU) (Apr 2015 – Jun 2016).
Basal Characteristics
Lenvatinib (n=75)
Median age, years (range)
65 (35 - 88)
Sex, n (%)
Male
42 (56)
Histology, n (%)
Papillary
Poorly Differentiated
Follicular
Oncocytic
32 (43)
19 (25)
22 (29)
2 (3)
Mutations BRAF/MET/ALK/RAS, n
6/1/0/3
≥ 1 Previous Systemic Treatment, n (%)
Targeted Therapy
Chemotherapy
50 (67)
8 (11)
No Previous Syst. Treatment, n (%)
24 (32)
Local Tx of Recurrence before LEN
Surgery
EBRT
23 (31)
36 (48)
Median time from RAIR to LEN mo (range)
32 (1 - 156)
Median time from Thdmy to LEN y (range)
5.9 (1.1 - 32.6)